Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE issues guidance on alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

Published: 18 June 2014

The National Institute for Health and Care Excellence (NICE) has issued guidance to the health service on the use of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis, based on a report produced by SHTAC.

NICE has issued guidance to the health service that alemtuzumab is recommended as a possible treatment for people with active relapsing-remitting multiple sclerosis.

NICE's guidance is based on an evidence review group report prepared by SHTAC, which critically appraised the drug manufacturer's submission to NICE's Single Technology Appraisal process.

Multiple sclerosis (MS) is a chronic, neurodegenerative disorder which leads, in most patients, to progressive neurological impairment and severe disability. Approximately 100,000 people in the UK have MS. Currently there is no cure for MS and treatments available aim to reduce the frequency and severity of relapses. Alemtuzumab is administered by intravenous infusion, the initial treatment course last 5 consecutive days in the first year of treatment, and over 3 consecutive days in the second year of treatment.

For more information on SHTAC's research into multiple sclerosis please visit our Research page.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.